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Background: Sickle cell anaemia (SCA) is an inherited disorder of haemoglobin. Patients experience long-term
health care problems, affecting quality of life (QOL) including frequent acute pain, which is difficult to document in
trials except as hospital admissions. Pilot data suggests that overnight respiratory support, either supplementary
oxygen or auto-adjusting continuous positive airways pressure (APAP), is safe and may have clinical benefit. This
pilot trial aims to determine which intervention is more acceptable to participants and whether there are other
advantages of one over the other, e.g. in respiratory function or haematological parameters, before conducting the
Phase 2 trial of overnight respiratory support funded by the National Institutes of Health Research.
Methods/Design: This is a pilot cross-over interventional trial with the order of interventions decided by simple
randomization. Ten adults (age over 18 years) and 10 children (aged between 8 and 18 years) with homozygous
sickle cell disease (haemoglobin SS, HbSS), recruited regardless of symptoms of sleep-disordered breathing, will
undergo overnight pulse oximetry and will have two interventions, overnight oxygen and APAP, for a week each in
randomised order with a washout week between interventions. Participants will complete online diaries via an iPad
throughout the 29 days of the study and will complete QOL questionnaires and have measurement of haematology,
biochemistry, spirometry and lung volumes (adults only) at 3 time points, at baseline and after each intervention, as
well as in-depth semi-structured qualitative interviews after each intervention, carried out by an experienced
psychologist. Both qualitative and statistical methods will be used to analyze the data. The primary outcome is
qualitative data looking at participant experience from the transcribed interviews after each intervention. The
participant’s view on feasibility, acceptability and preference will specifically be explored. The QOL, laboratory and lung
function data will be compared with baseline for each arm.
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Discussion: Patient and public involvement is an integral part of this trial and the key outcome is the qualitative result,
which is dependent on obtaining good quality data to advise on participant feasibility, acceptability and preference.
This is being addressed by using a standard interview. The development of a pain endpoint is another important
outcome and collecting daily measurements is likely to be challenging. Research results will be used to inform design
of the Phase 2 trial.
Trial registration: ISRCTN46078697 18 July 2014
Keywords: Sickle cell anaemia, Inherited diseases, Haemoglobin, Qualitative method, Statistical method, Randomised
controlled trialBackground
Sickle Cell Anaemia (SCA) is a recessively inherited dis-
order of haemoglobin, the protein which carries oxygen
inside red blood cells. SCA affects an estimated 15,000
people [1] in the UK and patients experience long-term
health care problems, including pain and neurocognitive
problems, which affect quality of life. Emergency presen-
tations are typically due to acute sickle cell pain [2, 3]
and account for over 6000 emergency admissions and
over 25,000 bed days per year [4]. Mortality in children
in England has improved over recent years with around
99 % now surviving to 18 years [5]. Life expectancy is,
however, shortened to 40–50 years [6, 7] and quality of
life is compromised by chronic complications [8–16].
The prevalences of intermittent nocturnal haemoglo-
bin oxygen desaturation, secondary to sleep-disordered
breathing, and sustained daytime and nocturnal haemo-
globin oxygen desaturation, are high in patients with SCA
[17–22]. There is an association between low oxygen sat-
uration (SpO2) and SCA complications, including stroke
[12, 23], enuresis [14] and priapism [15] as well as painful
crisis [3], although the latter is controversial [18], perhaps
related to differences in documentation of painful crisis.
Cognitive function, including impaired attention, is a
particular problem in SCA [24–29], and may be linked
to sleep-disordered breathing and oxygen desaturation
[25–29], as it is in the general population.
Treatment options for sleep-disordered breathing and
nocturnal hypoxia include continuous overnight oxygen
via a concentrator and continuous positive airways
pressure (CPAP) but there are few data on their use in
SCA. These two interventions commonly used to re-
duce overnight hypoxic exposure have different modes
of action and there are some preliminary data available
for each:
(1)Positive Airways Pressure. CPAP therapy reduces
sleepiness in adults and children with obstructive
sleep-disordered breathing in the general population
and may improve cognition and intermediate
vascular endpoints [30–33] but adherence is an
issue [31]. Auto-adjustable CPAP (APAP) is morecomfortable as the pressure support is only
triggered when the obstruction occurs [34].
Positive Airways Pressure in SCA Positive airways
pressure has been used short-term in SCA in acute
chest crisis [35] and to prevent peri-operative
complications [36]. In unselected children with
SCA in our 6-week proof-of-concept randomised
controlled trial (RCT), overnight respiratory support
with APAP was safe and feasible, with excellent
adherence in all 12 participants in the treatment
arm and no suppression of erythropoiesis [37].
Improvement in cancellation (Wechsler Intelligence
Scale for Children (WISC-IVUK)), a measure of
attention as well as processing speed, was seen in
those on APAP compared with those not treated
[37]. Pain frequency, defined as the number of days
that pain was experienced in a 2-week period,
improved in the treatment arm (p = 0.07) but this
did not reach statistical significance, perhaps related
to reduced statistical power due to reluctance to
complete paper pain diaries (full data was only
available for 8 of the 12 participants in each arm)
[37]. As pain is the cardinal symptom in sickle cell
disease, and is, therefore, an important endpoint in
clinical trials, ensuring that all participants complete
any diaries is important. With smartphone
technology [38], daily pain intensity and site may be
explored in addition to frequency [39], number of
days in hospital [3] or number of admissions [20].
(2)Overnight oxygen is well-established for the
treatment of hypoxia secondary to lung diseases,
such as chronic obstructive airways disease in adults
or bronchopulmonary dysplasia. Uncontrolled
hypercapnia is a risk in settings where respiratory
failure may occur [40].
Oxygen supplementation in SCA There are few data
on the safety of oxygen administration in people
with SCA and most data is available over short
periods of time, typically in the management of
acute crisis. The two main concerns in using
overnight oxygen in SCA are the suppression of
erythropoiesis and rebound pain, which has been
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rates of oxygen throughout 24-hour periods for
several days [41]. However, reticulocytosis was
documented in a child whose abdominal pain was
relieved by 18 days placement within an oxygen tent
[42]. In addition, erythropoietin levels did not fall in
non-hypoxic adults randomised to receive oxygen
during a painful crisis [43]. Although the duration of
painful crisis was not reduced by the administration
of oxygen in this study [43] or a paediatric trial
designed to administer 50 % oxygen [44, 45],
there was no evidence of rebound pain.
One report audited the use of long-term oxygen
supplementation in SCA. Ip et al [46] described
6 adults with SCA (age range 20–45 years; 4
women), who had been commenced on oxygen
therapy (1–2 l/minute) in the previous 2 years
because of nocturnal hypoxia, defined as oxygen
saturations < 90 % for > 30 % of the night. A
detailed case notes review showed a mean increase
in haemoglobin and reticulocyte count, with no
change in erythropoietin and painful episodes.There is a possibility that overnight respiratory sup-
port improves daytime lung function [47, 48] and oxy-
gen saturation. Both obstructive and restrictive lung
disease have been reported in patients with SCA [49]
and it is possible that there are physiological advantages
for overnight oxygen or APAP, e.g. in improving daytime
oxygen saturation [37] through improving gas exchange
by overcoming upper or lower airway obstruction or in-
creasing lung volume.
In addition to requiring additional safety data and ex-
ploring the physiological effects of overnight respira-
tory support, further work is needed to determine
whether one of these alternatives is preferable to pa-
tients in terms of the inconvenience when compared
with any possible benefits. To attempt to improve com-
pletion of diary data, the feasibility and acceptability of
daily data collection on presence, site and severity of
pain using a visual analogue scale for highest, pain and
lowest daily pain using smartphone technology on an
iPad mini (Apple Inc., Cupertino, CA, USA) also re-
quires assessment.
The National Institute of Health Research (NIHR) Re-
search for Participant Benefit (RfPB) stream has funded
our group to undertake a Phase 2 randomised 2-arm trial
of overnight respiratory support or standard treatment. As
there are very few pilot data involving treatment for sleep-
disordered breathing in this condition, it is important to
assess the acceptability of overnight oxygen supplementa-
tion compared with APAP in participants before deciding
on which form of overnight respiratory support to use as
the treatment arm in the Phase 2 trial. In the participantsand public involvement (PPI) work for the RfPB submis-
sion, no participant preference came out between the pro-
posed two interventions to help make a decision on which
intervention to choose, but these participants did not have
first-hand experience of using either device. This pilot
phase is designed to examine patient preferences after 1
week of using each device in randomised order and will
also determine whether there is evidence that either form
of overnight respiratory support has a short-term benefi-
cial or detrimental effect on haematological variables or
lung function.
Aims and objectives
The aim of this pilot study (Prevention of Morbidity in
SCA, POMS2a; Table 1) is to ascertain which intervention
(overnight oxygen or APAP) is more acceptable to partici-
pants by asking them to use both interventions for 1 week
each, with each intervention followed by an in depth
semi-structured qualitative interview. It will also assess the
quantitative methodologies, which are to be used in the
next larger trial (POMS2b, the Phase 2 trial).
There are 4 objectives for this study: (1) to assess
whether overnight oxygen therapy or APAP is more ac-
ceptable to participants, (2) to assess whether there are
any physiological or clinical benefits or risks of overnight
oxygen therapy or APAP, (3) to assess the feasibility of
using smartphone technology to collect daily informa-
tion on site and severity of pain and (4) to identify the
main cost drivers and potential cost implications of pro-
viding the intervention.
Methods/Design
The study was given approval by NRES Committee East
of England – Cambridge South (14/EE/0163) on 3 June
2014. Local ethical permission was granted by Guy’s and
St Thomas’ hospital NHS Foundation Trust. This is a
pilot cross-over interventional trial. Participants will
have 2 interventions, overnight oxygen and APAP, for a
week each in randomised order (weeks 2 and 4). There
will be a week of baseline data collection (week 1), and a
week of washout between the interventions (week 3).
Randomisation will be done by simple randomisation by
an independent statistician at the University of Southamp-
ton. It will not be possible to blind the participant, study
co-ordinator, sleep physiologist or psychologist to the
order of treatment. However, the principal investigator,
statistician and technician performing spirometry, i.e.
those responsible for documenting the quantitative
endpoints, will be blinded to which intervention is
given in which order.
Qualitative evaluation
At the end of each intervention period a qualitative inter-
view will be conducted by a psychologist. Participating
Table 1 Protocol details
Protocol title: Prevention of Morbidity in sickle cell disease 2a – pilot phase (Improvement of Pain and Quality of Life in
Participant with Sickle Cell Disease with Nocturnal Oxygen Therapy or Auto-adjusting Continuous Positive
Airways Pressure: pilot phase)
Protocol number and date Protocol Version 8 5February 2014
Protocol chair/principal investigator: Fenella Kirkham MD FRCPCH
Professor of Paediatric Neurology
Institute of Child Health (University College London)
Office: 44 207-905-2968
Fax: 44 207-833-9469
Email: fenella.kirkham@ucl.ac.uk
Protocol team/co-investigators: Prof David Rees MD MRCP MRCPath Dr Jo Howard MRCP FRCPath
Professor in Paediatric Haematology Consultant Haematologist
King's College Hospital Guy’s and St Thomas’ NHS Foundation Trust
Tel: 0207 346 3242 Tel: 0207 188 2741
Fax 0207 346 4689 Fax 0207 188 2728
Email: david.rees@kingsch.nhs.uk Email: jo.howard@gstt.nhs.uk
Dr Baba Inusa MB FRCPCH Prof Swee Lay Thein
Consultant Paediatrician, Professor of Molecular Haematology
Evelina Children’s Hospital, King’s College Hospital
London SE1 Tel: 0207 848 5443
Tel: 020 7177 7177 sl.thein@kcl.ac.uk
Email: Baba.Inusa@gstt.nhs.uk
Dr Christina Liossi Dr Nicholas Hart
Senior Lecturer in Health Psychology Consultant in Respiratory and Critical Care
University of Southampton Guy’s and St Thomas’ NHS
Tel: 02380594645 Foundation Trust
Fax Tel: 0207 188 7608
Email: cliossi@soton.ac.uk Email: Nicholas.hart@gstt.nhs.uk
Ms Carol Nwosu Dr Man Ying Edith Cheng
Chief Executive Officer Statistician
Sickle Cell and Young Stroke Survivors University of Southampton
Suite R, 7th Floor, Hannibal House Research Design Service
London UK UK
Tel : 0844209292 Tel: 02380795704
Email: Carolnwosu@scyss.org Email: m.y.cheng@soton.ac.uk
Associate Professor Ms Maria Chorozoglou
Assistant Professor Paediatrics Snr RF in Health Economics
Department of Nursing Wessex Institute
University of California Faculty of Medicine
Tel: 310 267 1823 University of Southamptom
Email: eufemia@sonnet.ucla.edu UK
Tel : 02380597457
Email: M.Chorozoglou@soton.ac.uk
Study sites Guy’s and St Thomas’ NHS Foundation Trust
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Table 2 Participant eligibility criteria for participation in the
POMS2a trial
Inclusion criteria
1 Recruitment will be through sickle cell clinics at Guy’s and St Thomas’
(including Evelina Children’s Hospital)
2 Age > 8 years
3 Informed consent with assent in accordance with the institutional
policies (UK ethical committee) and European or US Federal
guidelines must be signed by the participant or participant's parent
or legally authorised guardian acknowledging written consent to
join the study. Where appropriate, participants < 16 years will be
requested to give their assent to join the study
4 HbSS diagnosed by standard techniques (HPLC, IEF and MS).
Participating institutions must submit documentation of the
diagnostic haemoglobin analysis
5 Able to speak and understand English
6 Participant or parent/guardian able to use iPad mini via wireless
Exclusion criteria
1 Participant already on overnight respiratory support, or has used it
in the past
2 Hospital admission for acute sickle complication within the past 1
month
3 Participant with > 6 admissions for acute sickle complications within
the past 12 months
4 Existing respiratory failure
5 Decompensated cardiac failure
6 History of severe epistaxis
7 Trans-sphenoidal surgery, or trauma that could have left a
cranio-nasopharyngeal fistula
8 Perforated ear drum
9 Bullous lung disease
10 Bypassed upper airway
11 Pneumothorax
12 Participant at increased risk of aspiration
13 Pneumocephalus has been reported in a participant using nasal
Continuous Positive Airways Pressure. Caution should be used when
prescribing APAP for susceptible participants such as those with:
cerebral spinal fluid (CSF) leaks, abnormalities of the cribriform plate,
prior history of head trauma, and/or pneumocephalus
14 Pregnancy
15 Participants on chronic blood transfusion regimes, or has had blood
transfusion within past 3 months
16 Any acute or chronic condition which would limit the participant’s
ability to complete the study
Temporary exclusion criteria
17 Sinus or middle ear infection
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will be offered the choice of joint (children paired with
their parents) or separate interviews. Parents will provide
consent and children will be asked to assent in qualitative
interviews. Interviews will be tape-recorded and fully tran-
scribed. Inductive qualitative semi-structured interviews
will be used to gain a rich, in-depth understanding of par-
ticipants’ experiences and appraisals of oxygen therapy
and APAP across age groups and participant status (i.e.
patient versus carer).
Participants
This pilot study will involve 20 participants, recruited re-
gardless of symptoms of sleep-disordered breathing,
which includes 10 children (age between 8 and 18 years)
and 10 adults (age over 18 and above). All participants
will be enrolled into the study for 29 days (i.e. 4 weeks).
Consenting participants with HbSS who are aged > 8
years and attend at Guy’s and St Thomas’ NHS Founda-
tion Trust are eligible for this study. Participants will be
excluded if they already have overnight respiratory sup-
port, if they have existing respiratory or decompensated
cardiac failure or if they have any contra-indications to
APAP therapy. Both inclusion and exclusion criteria are
listed in Table 2.
Screening visit
Inclusion and exclusion criteria will be reviewed at the
screening visit. After the participant (and parents for
paediatric participants) have familiarised themselves with
the trial protocol and have given written informed con-
sent, relevant clinical history will be taken.
Procedure (Table 3, Fig. 1)
On day 1, the patient will attend the Day Care Unit at
the hospital and data including baseline blood tests,
PEDS-QL quality of life [50], daytime oximetry, will be
collected. Adults will undergo lung function (spirometry
and lung volume). The participant will be issued with an
iPad mini with a validated smartphone app [38] for rating
pain and symptom assessment and will be asked to
complete daily data collection using this device for the
duration of the whole study, taking approximately 5 mi-
nutes per day. They will be given an overnight oximeter to
take home and will be asked to use this for 2 nights over
the next week. The randomization codes will be provided
at the start of the study by an independent statistician
from the University of Southampton, who will use simple
randomization to generate the order.
On day 8, the participant will have the first intervention
(intervention 1), either oxygen or APAP, which will be de-
livered to their home and set up by the respiratory physi-
ologist, or if they prefer, they can take the treatment home
after explanation by the respiratory physiologist. They willbe asked to use this for 7 nights and will have planned
support calls (Fig. 1). The overnight oximeter will be
collected by the respiratory physiologist and the data
analysed. On day 15 the participant will return to the
hospital Day Care Unit for medical assessment, blood
tests, PEDS-QL quality of life assessment, daytime oximetry
and the first qualitative assessment with lung function
Table 3 Details of study flow and duration of each interventions period
Screening
visit
Trial entry
(Day 1)
Days
8–14
Days
15–21
Days
22–28
Day
29
Participant given PIS x
Inclusion/Exclusion reviewed x x
Consent signed x
Daytime oximetry x x x
Overnight oximeter issued x
Oximeter collected x
Spirometry x x x
Lung volume testing (adults) x x x
Quality of life evaluation x x x
Blood tests/urine tests x x x
Smartphone issued x
Daily pain diary for next week x x x x
Intervention 1 commenced x
Sleep physiologist to review participant at home to set up intervention 1, review
participant and adverse events
x
Intervention 1 stopped (courier to pick up) x
Intervention 2 commenced x
Sleep physiologist to review participant at home to set up intervention 2, review
participant and adverse events
x
Intervention 2 stopped (courier to pick up) x
Qualitative interview with participant and parent/guardian x x
Medical/nursing review of compliance and adverse event reporting x x
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with no intervention given, but ongoing daily data collec-
tion via the smartphone app on the iPad mini. On day 22
the participant will have the other intervention (interven-
tion 2) installed at home and they will be asked to use this
for the next 7 nights. On day 29, the participant will go to
the Day Care Unit at the hospital for medical assessment,
blood tests, PEDS-QL quality of life assessment, daytime
oximetry and lung function tests (adults) and the second
qualitative assessment. Adverse events and serious adverse
events will be reported to the sponsor (Tables 4 and 5).
The qualitative researcher will undertake interviews at
the end of both interventions for all 20 participants and
10 parents/guardians to determine participant preference
for one or other intervention. Participants will have a
phone call at days 9 and 23 from the sleep physiologist to
ensure they are using the equipment appropriately, and
further phone support will be available if necessary. The
sequence of the proposed investigations and the duration
of the trial period is given in Table 3 and the participants’
journey through the interventions is shown in Fig. 1.
Withdrawal criteria
Participants who wish to withdraw from the study are
free to do so. If this occurs they will be asked if theywould be willing for us to document withdrawal and the
reasons. Participants will be withdrawn if they experience
a serious adverse event and in this situation they will be
asked if they will continue with qualitative assessment if
appropriate. The trial intervention will be stopped if par-
ticipants are admitted to hospital with an acute sickle
complication. In this situation they will be asked if they
will continue with the qualitative assessment and if they
have only have received one intervention, if they would be
happy to have the second intervention.
All adverse events will be documented for these partici-
pants as if they had remained in the trial. They will be
asked to continue with qualitative assessments. Partici-
pants who withdraw may be replaced if appropriate partic-
ipants are available and consent to the study. Participants
will continue to be followed-up under the normal clinical
care pathway at Guy’s and St Thomas’ NHS Foundation
Trust. Participants who develop evidence of suppressed
erythropoiesis will discontinue the trial. If they have not
had a Parvovirus infection, the blind will be broken.
Interventions
The two interventions in this study are overnight oxygen
therapy and APAP. Both APAP and nocturnal oxygen
therapy are non-invasive. Support from a respiratory
Fig. 1 Flow chart for the interventions and support from the respiratory physiologist
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oxygen therapy will be available to maximise compliance
with the interventions (Fig. 1). Details of each of the in-
terventions are listed below:
Intervention: APAP
The REMstar® Auto System (Philips Respironics,
Chichester, UK) is an APAP device designed for theTable 4 Laboratory findings to be reported to the sponsor
within a maximum of 7 days
Variables Measurement level that may be consider as
adverse events
Haemoglobin Fall of > 20 g/l from baseline is significant
Reticulocytes 10–100 x 109 fall < 10 × 109 is significant
Lactate dehydrogenase Increase of > 1.5 x from baseline is significant.
Bilirubin Increase of > 1.5 x from baseline is significant
Creatinine Increase of > 1.5 from baseline is significant
Erythropoeitin Fall of > 50 % from baseline is significant
Oximetry Decrease in baseline oximetry of > 3 % from
baselinetreatment of obstructive sleep-disordered breathing.
When set in the APAP mode, the system will monitor
breathing whilst sleeping and automatically adjust the
pressure to overcome upper airway obstruction. APAP
will be administered via a nasal or oral-nasal mask.
APAP will be set at 4 cmH2O with an upper limit of 10
cmH2O.
Intervention: oxygen therapy
Nocturnal oxygen therapy: oxygen concentrator device
supplied by Philips Respironics (Chichester, UK). Oxygen
therapy is administered via nasal cannula or mask de-
pending on participant preference. Nocturnal oxygen
therapy will be administered at 0.5 L/min, in children
which was the level most commonly used in the previous
trial [37] and 1 L/min in adults.
Adherence to intervention
For the APAP arm, compliance and adherence to treat-
ment will be formally assessed using specially designed
software (Encore Pro™ data management software, Philips/
Respironics) and a SmartCard that records both qualitative
Table 5 The relationship between an adverse event and the
intervention
Type of adverse events
and relationship to the
intervention
Description
Unrelated • No temporal association to study intervention
• An alternative aetiology has been established
• The event does not follow the known pattern
of response to study intervention
• The event does not reappear or worsen with
re-challenge
Unlikely to be related • No temporal association to study intervention
• Event could readily be produced by clinical
state, environmental or other interventions
• The event does not follow the known pattern
of response to study intervention
• The event does not reappear or worsen with
re-challenge
Possibly related • Reasonable temporal relationship to study
intervention
• The event is not readily produced by clinical
state, environmental, or other interventions
• The event follows a known pattern of
response to the study intervention or as yet
unknown pattern of response
Definitely related • There is a reasonable temporal relationship to
the study intervention
• The event is not readily produced by clinical
state, environmental, or other interventions
• The event follows a known pattern of
response to the study intervention
• The event decreases with de-challenge and
recurs with re-challenge
Unassessable • Anything that does not fall into the above
categories
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assessed at the end of the 7-day intervention period. There
is no such capability for the oxygen concentrators and the
participant/carer will be asked to record the hours of use.
The sleep physiologist will phone participants at 24 hours
after starting each intervention and mid treatment. They
will provide further telephone support should study partici-
pants and their family have any questions/issues with the
study treatment or if participants identify a problem (Fig. 1).
Primary outcome
Measuring participant benefit
This is a qualitative study looking at participant experience
from the transcribed interviews after each intervention as
the primary outcome. The participant’s view on feasibility,
acceptability and preference will specifically be explored.
Established guidelines for thematic analysis will be
followed [51] and augmented with charting procedures
from framework analysis [52, 53]. First, one researcher willlisten to, read and reread the interviews and transcripts.
The interviews will be then coded line-by-line [53]. A cod-
ing manual will be created, and codes that appear most
useful to the research question will be applied to the rest
of the transcripts [53]. This analysis will be iterative, in-
volving constant comparison and refinement between
codes and transcripts to ensure that codes are being used
consistently and reflect the data. Codes identifying similar
aspects of the data will be clustered together under themes
and subthemes. Having identified the main themes, partic-
ipants will be grouped in a chart according to intervention
and participant status, and their talk that relates to each of
the themes will be summarised (based on the charting
techniques described in framework analysis [52, 53].
Secondary endpoints
Pain
Using the smartphone technology [38] which downloads
automatically, information on (a) pain characteristics
(intensity, location, quality), (b) pain medications and
non-pharmacological strategies used for pain, (c) health
care visits will be collected in the pilot to test out the
methodology and to determine whether there is any ob-
vious effect of either intervention or its withdrawal,
particularly if detrimental. This is important as the first
outcome measure for trial 2b will be average pain in-
tensity during the 2 observation periods.
Adverse events
The Clinical Report Forms (CRFs) for reporting adverse
events will be trialled during this pilot to show efficacy
in recording and reporting adverse events.
Daytime oxygen saturation will be collected before and
after each intervention to determine whether there is
any obvious effect of either intervention or its with-
drawal, particularly if detrimental.
Lung function
Spirometry and lung volume will be collected before and
after each intervention to determine whether there is
any obvious effect of either intervention or its with-
drawal, particularly if detrimental.
Quality of life data
Age appropriate versions (paediatric or adult) of the
PEDS-QL quality of life measure [50], including the
sickle module, will be collected at the beginning of trial
and after each intervention to determine whether there
is any effect of either intervention.
Safety measurement
Safety assessment will be undertaken by the chief investi-
gator (FJK) liaising with the local adult (JH) and paediatric
(BI) principal investigators at the local sites by (1) review
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(2) review of basic haematological and biochemical pa-
rameters at days 1, 15 and 29. This will include full
blood count, reticulocyte count, lactate dehydrogenase
(LDH), bilirubin, creatinine, erythropoietin, albumin
creatinine ratio and (3) daytime oximetry at days 1, 15
and 29. The value(s) or range(s) for medical, laboratory
and/or technical procedure(s) are given in Table 6.
Statistical analysis
The preliminary data on participant preference and
physiology will be analysed at the end of this pilot phase
and will be used to make a final decision about which
intervention should be used for trial 2b (the Phase 2
study). This is a pilot phase; all statistical analyses will
be treated as preliminary and exploratory and will
mainly be descriptive [54]. We will investigate factors
that influence recruitment rate, acceptability, adherence
and loss to follow-up. The variability of outcome mea-
sures will be reported and any indication of improvement
on any of the treatment will be explored informally: e.g.
daily pain rate from the smartphone app, admissions to
hospital for complications and laboratory parameters. The
decision will be made primarily according to participant
preference and, if this is at equipoise, on any apparent
physiological benefits, e.g. higher daytime oxygen satura-
tions, improved lung function or rates of adverse events.
The cost implications will be assessed and relative long-
term costs to the NHS will be taken into account if there
is still equipoise.
The study will be reported in accordance with the
CONSORT (Consolidated Standards of Reporting Trials)
2010 statement (Additional file 1) (or latest version if it
is available at the time of reporting) [55]. A baseline
table will be included to compare important demo-
graphic and clinical characteristics between those who
started intervention 1 first and those who started inter-
vention 2 first. In total there 3 time points, baseline,
after intervention 1 and after intervention 2; all variablesTable 6 Normal measurement range
Parameters Normal measurement and range
Pain diary Pain rates whilst receiving the intervention will
be reviewed with baseline pain rates
Haemoglobin 130–170 g/l normal range in men,
120–150 g/l in women, 115–145 g/l in children
Haemoglobin F % 0–1.5 %
Reticulocytes 10–100 x 109
Lactate dehydrogenase 24–280 IU/l
Bilirubin 0–21 μmol/l
Creatinine 45–85 μmol/l
Erythropoietin 5–25 IU/l
Daytime oximetry >94 %will be reported at all 3 time points. Any deviations from
the original statistical plan will be incorporated, with full
explanation, into a revised version of the protocol.
Discussion
This is a pilot cross-over interventional trial involving
children and adults with SCA. Patient and public in-
volvement has been an integral part of this trial and the
key outcome is qualitative and dependent on obtaining
good quality data to advise on participant feasibility, ac-
ceptability and preference. This is being addressed by
using a standard interview, which is carried out by a des-
ignated psychologist. The development of a pain end-
point is another important outcome and collecting daily
measurements is likely to be challenging. This has been
addressed by using smartphone technology via an iPad
mini, which can connect to wireless networks but does
not require a phone contract [38], which is cost-effective
and should be easier for participants to complete. As-
sessment of the usefulness of this technology is import-
ant as the first outcome measure for the Phase 2 trial,
POMS2b, will be average pain intensity during the 2 ob-
servation periods and we plan to use the same technol-
ogy if this proves successful in the pilot. For this pilot
study, we are including patients regardless of pain fre-
quency and severity, although it is possible that patients
with a significant burden of pain might have a different
spread of preferences. In the Phase 2 trial there is a case
for including only patients with chronic pain, screened
with an appropriate questionnaire for burden of pain
[56]. The patient’s experiences and acceptability of both
interventions, and statistical evaluation of pain, adverse
events, safety data and physiological data will all be
taken into account to determine the most acceptable
intervention. The most acceptable intervention will be
used in the second phase of the larger proof-of-concept
study (POMS2b).
A potential risk is that the participants and their families
do not feel adequately supported to agree to recruitment
or to continue in their allocated intervention. The sleep
physiologist (who will not be blinded to the interventions)
will provide easily accessible advice and support. She will
routinely call the patient the day after the intervention has
started but will also be available to answer additional ques-
tion during the time of the intervention. Recruitment may
also be a challenge but experienced clinical haematologists
are co-applicants in order to maximise the chance of
steadily recruiting participants who will commit to the
study and also remember to complete the online pain
score at daily bases. The team has experience of similar
trials with the same group of participants, for which it has
successfully recruited.
The findings from this pilot study will be disseminated
to the scientific community, service users and policy-
Howard et al. Trials  (2015) 16:376 Page 10 of 11makers via submission to an Open Access peer-review
journal. In addition the patient public involvement rep-
resentatives are taking the lead to disseminate the find-
ings to the service users.
Trial status
The trial is still recruiting.
Additional files
Additional file 1: CONSORT checklist. (PDF 70 kb)
Additional file 2: Personal cover image 1: Study logo. (DOC 21 kb)
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